Advice
Following a full submission
Bemiparin (Zibor) is not recommended for use within NHS Scotland for the prevention of clotting in the extracorporeal circuit during haemodialysis.
It showed similar efficacy to unfractionated heparin in preventing coagulation in the extracorporeal circuit but has not been compared with other low molecular weight heparins.
No evidence of the cost effectiveness of bemiparin during haemodialysis has been presented by the manufacturer.
Download detailed advice40KB (PDF)
Medicine details
- Medicine name:
- Bemiparin, 2500 IU in 0.2 ml and 3500 IU in 0.2 ml, injection for sub-cutaneous administration (Zibor®)
- SMC ID:
- 205/05
- Indication:
- Prevention of clotting in extracorporeal circuit during haemodialysis
- Pharmaceutical company
- Amdipharm PLC
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 10 October 2005